Jun Li

Jun Li
Henan Cancer Hospital · Molecular Pathology

PhD

About

26
Publications
3,413
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
302
Citations

Publications

Publications (26)
Article
Full-text available
Lung adenocarcinoma (LUAD) is the most predominant histological subtype of lung cancer characterized by driver mutations detected in a substantial proportion of the cases. Tyrosine kinase inhibitors (TKIs) are standard care for the patients with these mutations. In this study, we evaluated the efficiency of an NGS-based 8-gene test in selecting TKI...
Article
Full-text available
Tumor heterogeneity is associated with poor prognosis and drug resistance, leading to therapeutic failure. Here, we used tumor evolution analysis to determine the intra- and intertumoral heterogeneity of high-grade serous ovarian cancer (HGSOC) and analyze the correlation between tumor heterogeneity and prognosis, as well as chemotherapy response,...
Article
Full-text available
Esophageal cancer (EC) is a multifaceted disease. Our understanding of the involvement of esophageal microbiota in its pathogenesis and progression is limited, which is due to the lack of proper endoscopic sampling methods. Hereby, we conducted a comparative analysis of paired samples obtained through endoscopic brushing and cytosponge, aiming at a...
Article
Full-text available
Backgroud Multiple studies have identified pathogenic germline variants in cancer susceptibility genes (CSGs) in Chinese lung cancer patients; however, accurate assessment of these variants' contributions to cancer predisposition is always hampered by the absence of data on the prevalence of these variants in the general population. It is necessary...
Article
Full-text available
Esophageal cancer (EC) is an aggressive malignancy with a poor prognosis. Various factors, including dietary habits, and antacid and antibiotic use, have been shown to influence the esophageal microbiome. Conversely, enrichment and diversity of the esophageal microbiome can also impact its function. Recent studies have revealed prevalent changes in...
Article
Full-text available
As homologous recombination deficiency (HRD) is a biomarker to predict the efficiency of PARP inhibitor treatment, this study developed a non-exonic single-nucleotide polymorphism (SNP)-based targeted next-generation sequencing (Tg-NGS) panel and comprehensively examined it both on standards and clinical ovarian cancer tissues. The HRD scores calcu...
Article
Full-text available
Introduction Transformation from lung adenocarcinoma (LUAD) to small cell lung cancer (SCLC) is one of the mechanisms responsible for acquired EGFR-TKIs resistance. Although it rarely happens this event determines a rapid disease deterioration and needs specific treatment. Patient and method We report a case of 75-year-old LUAD female with a p.L85...
Preprint
Full-text available
Background: Lung adenocarcinoma (LUAD) is the most predominant histological subtype of lung cancer characterized by driver mutations detected in a substantial proportion of the cases. Tyrosine kinase inhibitors (TKIs) are standard care for the patients with these mutations. In this study, we evaluated the efficiency of an NGS-based 8-gene test in s...
Article
Full-text available
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with limited treatment options. To guide the design of more effective immunotherapy strategies, mass cytometry was employed to characterize the cellular composition of the PDAC-infiltrating immune cells. The expression of 33 protein markers was examined at the single-cel...
Article
Full-text available
Breast cancer gene 1 (BRCA1) and BRCA2 are tumor suppressors involved in DNA damage response and repair. Carriers of germline pathogenic or likely pathogenic variants in BRCA1 or BRCA2 have significantly increased lifetime risks of breast cancer, ovarian cancer, and other cancer types; this phenomenon is known as hereditary breast and ovarian cance...
Article
Full-text available
Recently, combination regimens based on programmed cell death-1 (PD-1) blockade have become increasingly common in clinical practice for the treatment of cancer. Such combinations significantly improve efficacy, but treatment-related adverse events have also become more complex and severe. Here, we report an acute toxic epidermal necrolysis (TEN)-l...
Article
Full-text available
Predisposition of germline BRCA1/2 mutations (gBRCAMUT ) increases the risk of breast and ovarian cancer in females, but the mutation prevalence and spectrum are highly ethnicity-specific with different recurrent mutations being reported in different populations. Hereby, we performed hybridization-based target sequencing of BRCA1/2 in 530 ovarian c...
Article
e13139 Background: Lung cancer is the most common and lethal malignancy throughout the world, in which non-small cell lung cancer (NSCLC) is the dominant subtype. To distinguish between different cell types of NSCLC, i.e. adenocarcinoma or squamous cell carcinoma, the morphologic features of cancer cells are important, as well as specific molecular...
Article
e13018 Background: In recent years, the prognosis of non-small cell lung cancer (NSCLC) patients has been substantially improved by targeted therapies against specific molecular aberrations, i.e. tyrosine kinase inhibitors (TKIs) for Epidermal Growth Factor Receptor ( EGFR) etc. Several genes have been suggested by NCCN guideline (v7.2017) to test...
Article
Full-text available
Acquired resistance to EGFR‐tyrosine kinase inhibitors (TKIs) is a prevalent clinical problem in the management of advanced non‐small cell lung cancer (NSCLC) with TKI‐sensitizing mutations in the EGFR gene. Third‐generation EGFR‐TKIs have demonstrated potent activity against TKI resistance mediated by the EGFR T790M mutation, and standard re‐biops...
Article
Full-text available
T790M secondary mutation in EGFR is the most well-established EGFR-TKIs resistant marker in non-small-cell lung cancer (NSCLC). The current methods to rapidly and accurately detect T790M in clinical practice are not satisfactory because of several obstacles, including unavailability of tumor tissue re-biopsies and low DNA copy number of T790M in ci...
Article
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.
Article
Full-text available
SET domain-containing 2 (SETD2) is responsible for the trimethylation of histone H3 lysine36 (H3K36me3) and is one of the genes most frequently mutated in clear cell renal cell carcinoma (ccRCC). It is located at 3p21, one copy of which is lost in the majority of ccRCC tumors, suggesting that SETD2 might function as a tumor suppressor gene. However...
Data
Overview of All Oligo- and Primer Sequences.
Data
Genes that Significantly Changed in the One-Way ANOVA Test of Three Groups of Samples: SETD2-WT PTECs at Day 6, SETD2-WT PTECs at Day 16, and SETD2-KD PTECs at Day 25.
Data
Supplementary Material and Methods. Schematic representation of the workflow and detailed experimental procedures
Article
Full-text available
In the past decade important progress has been made in our understanding of the epigenetic regulatory machinery. It has become clear that genetic aberrations in multiple epigenetic modifier proteins are associated with various types of cancer. Moreover, targeting the epigenome has emerged as a novel tool to treat cancer patients. Recently, the firs...

Questions

Questions (2)
Question
Recently, I had some discussion with another colleague about the classification of variants detected in our routine clinical care. Here's an example, the gene A is involved in homologous recombination repair, truncating mutation in A increased the risk of developing breast/ovarian cancer, or other cancers.We detected a missense variant in gene A, but the population frequency of this variant, let's say 1.5%, is higher than the occurance of this risease (3/10000); meanwhile, there are other evidence, functional study or in silico prediction, show that the change leads to HR defect.
In my personal perspective, I woud give a higher weight to the population frequency. Although functional study or in silico prediction shows this variant leads to HRD, the carriers didn't show increased cancer risk; therefore, I would consider this variant as benign OR likely benign.
My colleague, however, has a different opinion that she would like to classify this variant as VUS (variant of unknown significance), since the evidence from population frequency and functional consequences are contradict to each other.
May I know your opinion ? I would appreciate your sharing.
Question
Hereditary breast and ovarian cancer (HBOC) syndrome is an inherited cancer-predisposition syndrome. If a germline BRCA1/2 pathogenic mutation carrier hasn't develop any cancer yet, should I also define this case as a HBOC syndrome because of her high risk of developing cancer ?

Network

Cited By